Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.
Options
BORIS DOI
Date of Publication
2017
Publication Type
Article
Division/Institute
Contributor
Scully, M | |
Cataland, S | |
Coppo, P | |
de la Rubia, J | |
Friedman, K D | |
Matsumoto, M | |
Pavenski, K | |
Sadler, E | |
Sarode, R | |
Wu, H |
Subject(s)
Series
Journal of thrombosis and haemostasis
ISSN or ISBN (if monograph)
1538-7836
Publisher
Wiley-Blackwell
Language
English
Publisher DOI
PubMed ID
27868334
Uncontrolled Keywords
Description
BACKGROUND
Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are two important acute conditions to diagnose. Thrombotic Microangiopathy is a broad pathophysiological process that leads to microangiopathic hemolytic anemia, thrombocytopenia and involves capillary and small vessel platelet aggregates. The most common cause being disseminated intravascular coagulation (DIC), which may be differentiated by abnormal coagulation. Clinically, a number of conditions present with microangiopathic hemolytic anemia and thrombocytopenia (MAHAT), including cancer, infection, transplantation, drugs, autoimmune disease and pre-eclampsia and HELLP (Hemolysis, Elevated Liver enzymes, Low Platelet count) syndrome in pregnancy. Despite overlapping clinical presentations, TTP and HUS have distinct pathophysiology and treatment pathways.
OBJECTIVES
Presented is a consensus document from an international working group on TTP and associated TMAs (thrombotic microangiopathies).
METHODS
The international working group has proposed definitions and terminology based on published information and consensus based recommendations.
CONCLUSION
The consensus aims to aid clinical decisions but also future studies and trials, utilizing standardized definitions. It presents classification of the causes of TMA, and criteria for clinical response, remission and relapse of congenital and immune mediated TTP. This article is protected by copyright. All rights reserved.
Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are two important acute conditions to diagnose. Thrombotic Microangiopathy is a broad pathophysiological process that leads to microangiopathic hemolytic anemia, thrombocytopenia and involves capillary and small vessel platelet aggregates. The most common cause being disseminated intravascular coagulation (DIC), which may be differentiated by abnormal coagulation. Clinically, a number of conditions present with microangiopathic hemolytic anemia and thrombocytopenia (MAHAT), including cancer, infection, transplantation, drugs, autoimmune disease and pre-eclampsia and HELLP (Hemolysis, Elevated Liver enzymes, Low Platelet count) syndrome in pregnancy. Despite overlapping clinical presentations, TTP and HUS have distinct pathophysiology and treatment pathways.
OBJECTIVES
Presented is a consensus document from an international working group on TTP and associated TMAs (thrombotic microangiopathies).
METHODS
The international working group has proposed definitions and terminology based on published information and consensus based recommendations.
CONCLUSION
The consensus aims to aid clinical decisions but also future studies and trials, utilizing standardized definitions. It presents classification of the causes of TMA, and criteria for clinical response, remission and relapse of congenital and immune mediated TTP. This article is protected by copyright. All rights reserved.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| JKH_Scully_et_al-2016-Journal_of_Thrombosis_and_Haemostasis.pdf | text | Adobe PDF | 202.88 KB | publisher | accepted | ||
| jth13571.pdf | text | Adobe PDF | 223.7 KB | publisher | published |